ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
David R Jones
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, D. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jones, D. R.

Ann Thorac Surg 2001;71:1639
© 2001 The Society of Thoracic Surgeons

Invited commentary

David R Jones, MDa

a Department of Thoracic and Cardiovascular Surgery, University of Virginia, PO Box 800679, Charlottesville, VA 22908-0679, USA

(Email: djones@virginia.edu).

The first 20% of the full text of this article appears below.

While primary thoracic sarcomas are rare, their treatment remains difficult for the thoracic surgical oncologist. The primary treatment for thoracic sarcomas has gradually evolved into a multimodal approach, with many patients undergoing induction chemoradiotherapy followed by surgical resection with or without brachytherapy. Despite this aggressive approach, these tumors frequently have locoregional recurrence at the resection margins and may have distant metastasis as well.

Tumor angiogenesis is involved in both the . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by The Society of Thoracic Surgeons.